- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03134170
Effect of Pharmacists Treating Diabetes in a FQHC
Impact of Adding a Pharmacist to the Health Care Team in a Federally Qualified Health Center
연구 개요
상세 설명
We will put all patients into one of two groups by chance (like flipping a coin). One group of 80 patients will get the regular care at the clinic (control group). The other group of 80 patients will get their regular care at the clinic plus care by a pharmacist. The pharmacist and the regular provider will work as a team to manage the patient's drug therapy (Intervention group).
We will test the status of the patient's diabetes at each visit. Tests may include:
- Measuring weight, heart rate, and blood pressure
- Finger stick with a small needle to check lipid (fat) concentrations, fasting blood sugar or HbA1c
- Examining feet, skin, and eyes
- Reviewing the patient's diary of blood sugars, diet, and exercise history
- Filling out a survey that measures quality of life and problems that make it hard to control your diabetes
- Referral to other specialists such as a podiatrist (foot doctor), optometrist (eye doctor), nutritionist, and dentist
Patients will have appointments with their current provider and possibly with the pharmacist at least every 3 months. However, the total number of appointments is based on the patient's health needs. The first appointment with the pharmacist will take about one hour. Additional appointments will take about 30 minutes.
The group without the pharmacist will have regular appointment times. After 12 months in the study if the patients glucose is not well controlled they can be treated by the pharmacist for 6 months.
Final measures will be made after 12 mont
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New Jersey
-
Trenton, New Jersey, 미국, 08618
- Henry J Austin Health Clinic
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 and 74
- Medicaid insurance
- HbA1c of 8% or greater
Exclusion Criteria:
- HbA1C greater than 15% because the finger stick device can not accurately read values greater than this unless the HbA1C can be confirmed with a value drawn in the laboratory.
- Age < 18 years old or age ≥ 75 years old
HbA1c < 8.5% PLUS presence of one or more of the following regardless of age:
- Limited life expectancy
- History of severe hypoglycemia
HbA1c < 8.5% PLUS presence of one or more of the following if age ≥ 65 years old:
- Residency in a long-term care facility (e.g. nursing home, adult family home, etc.)
- ≥ 3 co-existing chronic illnesses c
- Impairments in ability to perform two or more instrumental activities of daily living d
- Mild, moderate, or severe cognitive impairment as determined by the patient's provider and Mini-Cog test
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: No intervention
The no intervention group will serve as control group.
This group will receive standard care and will be an active comparator.
At the end of the study they may join the intervention group
|
|
|
다른: Intervention group
The intervention group will be seen by a pharmacist iin addition to their normal provider.
The pharmacist will provide medication therapy review of the patient's therapy.
The pharmacist will make recommendations to make revisions in the patient's therapy.
|
Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hemoglobin A1C
기간: every 3 months for one year
|
Plasma glucose control
|
every 3 months for one year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Preventative care
기간: Baseline 6 months and 12 months
|
How frequent does the patient see a dentist, podiatris, optomitrist,
|
Baseline 6 months and 12 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Caitlin McCarthy, PharmD, Rutgers, Earnest Mario School of Pharmacy
간행물 및 유용한 링크
일반 간행물
- Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008 Apr;28(4):421-36. doi: 10.1592/phco.28.4.421.
- Wallack MC, Loafman M, Sorensen TD. The Patient Safety and Clinical Pharmacy Collaborative: improving medication use systems for the underserved. J Health Care Poor Underserved. 2012 Aug;23(3 Suppl):96-102. doi: 10.1353/hpu.2012.0143.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제2형 당뇨병에 대한 임상 시험
-
Postgraduate Institute of Medical Education and...완전한
-
Hangzhou SynRx Therapeutics Biomedical Technology...모병유방암 | 난소 암 | 고급 고형 종양 | 전이성 고형 종양 | BRCA 1/2 및/또는 HRD중국
Pharmacist review of therapy에 대한 임상 시험
-
Vyaire Medical아직 모집하지 않음